Navid Sobhani, Ph.D
Picture

Navid Sobhani, Ph.D
Postdoctoral Fellow
Positions
- Postdoctoral Fellow
-
Medicine - Epidemiology & Population Science
Baylor College of Medicine
Houston, US
- Ph.D Degree
-
Department of Medical, Surgical and Health Sciences
University of Trieste
Trieste, Friuli Venezia Giulia Italy
Investigation of the prognostic and drug-predictive role of the immune system in solid tumors.
- Associate Researcher
-
Department of Cancer Stem Cells
Istitute of National Health
Rome, Lazio Italy
Biological evaluation of the efficacy of peptide-drug conjugates drug delivery to cancer cells and cancer stem cells.
- Associate Researcher
-
Department of Chemical Engineering and Biotechnology
University of Cambridge
Cambridge, Cambridgeshire United Kingdom
• Developed novel methods for blood based biomarker discovery in Schizophrenia using LC-MSe and MRM mass spectrometry. • Implemented an efficient method for exosome isolation from serum for proteomic profiling.
- MSc Thesis
-
Institute FIRC of Molecular Oncology
IFOM
Mlilan, Lombardia Italy
• Explored the opposing role of TALE family transcription factors Meis 1 and Prep 1 proteins in breast cancer pathogenesis, through infection of MCF10A with vectors altering expression level of these two proteins.
Addresses
- One Baylor Plaza (Office)
-
Houston, TX 77030
United States
Education
- PhD from University of Trieste
- 03/2020 - Trieste, Italy
- MS from University of Cambridge
- 12/2014 - Cambridge, United Kingdom
- MSc from University of Aberdeen
- 07/2013 - Aberdeen, Aberdeenshire United Kingdom
Professional Interests
Selected Publications
- "PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.." EBioMedicine.2017/August;22:18-19. Pubmed PMID: 28688823
- "Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer." Invest. New Drugs.2018/December;36:1133–1137. Pubmed PMID: 30083960
- "Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer." Cells.2018/July;7(76): Pubmed PMID: 30011957
- "C32Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: a literature based meta-analysis of randomized trials.." Annals of Oncology.2016/November;:
- "Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.." Cells. 2018 : Pubmed PMID: 30622925
- "Advances in systemic therapy for metastatic breast cancer: future perspectives." Med. Oncol.. : Pubmed PMID: 28526922
- "The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.." J Cell Biochem. 2018 119 : 4287–4292.
- Navid Sobhani, Chunmei Fan, Pedro O. Flores-Villanueva, Daniele Generali and Yong Li "The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments." IJMS. 2020 March 16; 21 (6): Pubmed PMID: 25400686
- "Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?." 2020 May 12; :
- "Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study." Breast Cancer Res Treat. 2020 August 7; : Pubmed PMID: 32770287
- "CTLA-4 in Regulatory T Cells for Cancer Immunotherapy." Cancers. 2021 March 22; 13 (6): 1440.
- "Cancer/Testis Antigens: from Serology to mRNA Cancer Vaccine." Seminars in Cancer Biology. 2021 April 25; :
- "Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer." Cells. 2021 February 1; : Pubmed PMID: 33535617
- "Tumour Infiltrating Lymphocytes and Immune-Related Genes as Predictors of Outcome in Pancreatic Adenocarcinoma." PLoS One. 2019 14 (8): Pubmed PMID: 31381571
- "Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma." Mol Biol Rep. 2019 March 6; 46 : 2713–2720. Pubmed PMID: 30840203
- Navid Sobhani, Alberto D’Angelo, Xu Wang, Ken H. Young, Daniele Generali and Yong Li "Mutant p53 as an Antigen in Cancer Immunotherapy." IJMS. 2020 June 3; 21 (11):
- "MR1-Restricted T Cells in Cancer Immunotherapy." Cancers. 2020 August 3; 12 (8):
- "AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption." 2021 : Pubmed PMID: 34073713
- "Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma." Genes Cancer. 2017 March ; 8 : 495–496. Pubmed PMID: 28680533
- "p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis." Molecules. 2021 October 28; 26 (20): 6215. Pubmed PMID: 34684792
- "Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects." International Immunopharmacology. 2021 October ; :
- "Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer." Cancer Chemother Pharmacol. 2019 24 (4): 669-677. Pubmed PMID: 31187168
- "Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer." WJCO. 2020 June 24; 11 (7): 450-463. Pubmed PMID: 32821651
- "Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?." World J Clin Oncol. 2018 9 (2): 26-32. Pubmed PMID: 5893994
- "Avelumab in gastric cancer.." Immunotherapy. 2019 : Pubmed PMID: 31060469
- "Cabozantinib as a second-line treatment option in hepatocellular carcinoma." 2020 May 12; :
- "Corticosteroid switch after progression on abiraterone acetate plus prednisone.." Int J Clin Oncol.. 2020 November 8; : Pubmed PMID: 31705219
- "Current status of PI3K-mTOR inhibition in hormone- receptor positive, HER2-negative breast cancer.." World J Clin Oncol. 2018 November 26; 9 (8): 172-179. Pubmed PMID: 30622925
- "Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies." Cancers. 2020 November 6; 12 (11): 3293.
- "Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? Invest.." Invest New Drugs. 2019 37 : 1274–1288. Pubmed PMID: 30879152
- Navid Sobhani, Bruna Scaggiante, Rachel Morris, Dafei Chai, Martina Catalano, Dana Rae Tardiel-Cyril, Praveen Neeli, Giandomenico Roviello, Giuseppina Mondani, Yong Li "Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials." Cancer Treatment Review. 2022 June 22; 109 : 102429. Pubmed PMID: 35759856
- "Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer." Cancers. 2022 June 15; 14 (12): 2952. Pubmed PMID: 35740618
- "IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy." Cancers. 2022 June 9; 14 (12): 2861. Pubmed PMID: 35740527
- "Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer." Cancers. 2020 November 10; 12 (11): 3314.
- "Advances in anti-BRAF therapies for lung cancer." 2021 January 21; : Pubmed PMID: 33474634
Projects
- AI-Assisted Therapeutic CTLA-4 Strategies
- Baylor College of Medicine
- Using Artificial Intelligence (AI) I would like to have millions of possible targeting compounds screened to find the best cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors to elicit an immune-response to solid tumors. CTLA-4 plays an important role in hindering the anticancer immunity and novel solutions to therapeutically intervene could prove of a great benefit in advanced tumors. After detecting the most efficient leads I would like to investigate their mode of action in cancer cells. In an area where FDA-approved immunotherapies targeting CTLA-4 and PD-1/PD-L1 elicit strong antitumor T-cell responses in various types of cancers, there is still a lack to completely understand the role of T-cells in cancer immunology. The area excites my interest to pioneer new structures that could powerfully elicit the immune system while lowering adverse events. In this context I am looking at the two roles of CTLA-4: from one side antagonist can be used to boost the immune system against cancer; on the other side agonist could be used to block the immune reactions in the context of auto-immune diseases and more spectacularly it would be great to have drugs efficient against SARS and the current COVID-19.
- DNA Therapeutic Cancer Vaccine Delivery Against PD-1
- Baylor College of Medicine (05/2020 - present)
- As the field of vaccination has been tremendously growing culminating with FDA-approval of great RNA vaccines against COVID-19, I would like bridge this field with the production of RNA- or even DNA-based cancer vaccines. Ferritin nanoparticle is a self-assembling multimeric vaccine platform that has been used previously for displaying antigens like Influenza and Epstein-Barr virus. Currently, I am looking into the generation of DNA vaccines against PD-1 in ferritin nanoparticle, possibly improving current methods of Plasmid delivery in-vivo through different techniques.
Intellectual Property
- NEW AND MORE 'POWERFUL MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF neuroendocrine tumors (NETs) E OF STEM CELLS OF NETs
- Product Patent (Approved)
Languages
Italian, Farsi
Log In to edit your profile